17 results on '"Johnny J. Wei"'
Search Results
2. Supplementary Figure 1 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Supplementary Figure 1: Validation of RWV-366T - PDF file 5154K, Verification of renal origins and confirmation of patient tissue match for RWV-366T ccRCC cell line
- Published
- 2023
- Full Text
- View/download PDF
3. Supplementary Figure 5 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Supplementary Figure 5: mono and combo effects of temsirolimus - PDF file 350K, Monotherapeutic Dose out of the mTOR inhibitor temsirolimus in ccRCC cell lines
- Published
- 2023
- Full Text
- View/download PDF
4. Supplementary Figure 2 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Supplementary Figure 2: Inhibition of SCD1 induces ER stress - PDF file 1316K, Inhibition of SCD1 activity in ccRCC induces endoplasmic reticulum stress response in ccRCC
- Published
- 2023
- Full Text
- View/download PDF
5. Supplementary Figure Legend from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Supplementary Figure Legend - PDF file 92K, Figure legends for Supplementary Figures
- Published
- 2023
- Full Text
- View/download PDF
6. Data from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Purpose: We set out to identify Stearoyl-CoA desaturase 1 (SCD1) as a novel molecular target in clear cell renal cell carcinoma (ccRCC) and examine its role in tumor cell growth and viability in vitro and in vivo independently as well as in combination with current U.S. Food and Drug Administration (FDA)-approved regimens.Experimental Design: Patient normal and ccRCC tissue samples and cell lines were examined for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through use of a small molecule inhibitor, A939572, were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Therapeutic models of synergy were evaluated utilizing pharmacologic inhibition of SCD1 with the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus.Results: Our studies identify increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decreased tumor cell proliferation and induced apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of A939572-treated or SCD1 lentiviral knockdown samples, induction of endoplasmic reticulum stress response signaling was observed, providing mechanistic insight for SCD1 activity in ccRCC. Furthermore, combinatorial application of A939572 with temsirolimus synergistically inhibited tumor growth in vitro and in vivo.Conclusions: Increased SCD1 expression supports ccRCC viability and therefore we propose it as a novel molecular target for therapy either independently or in combination with an mTOR inhibitor for patients whose disease cannot be remedied with surgical intervention, such as in cases of advanced or metastatic disease. Clin Cancer Res; 19(9); 2368–80. ©2013 AACR.
- Published
- 2023
- Full Text
- View/download PDF
7. Supplementary Data from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Supplementary Data from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Published
- 2023
- Full Text
- View/download PDF
8. Supplementary Figure 4 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
- Author
-
John A. Copland, Han W. Tun, Winston W. Tan, Kevin Wu, Thomas R. Caulfield, Simon J. Cooper, Johnny J. Wei, Laura A. Marlow, and Christina A. von Roemeling
- Abstract
Supplementary Figure 4: mono and combo effects of pazopanic and sunitinib - PDF file 1678K, Monotherapeutic dose out of pazopanib and sunitinib, and combinatorial effects with SCD1 inhibitor in ccRCC cells
- Published
- 2023
- Full Text
- View/download PDF
9. Effect of pre-injection opioid use on post-injection patient-reported outcomes following epidural steroid injections for radicular pain
- Author
-
Silky Chotai, Clinton J. Devin, Byron J Schneider, Ahilan Sivaganesan, Aaron J. Yang, Johnny J. Wei, and Kristin R. Archer
- Subjects
Adult ,Male ,medicine.medical_treatment ,Injections, Epidural ,03 medical and health sciences ,0302 clinical medicine ,Back pain ,Humans ,Medicine ,Orthopedics and Sports Medicine ,Patient Reported Outcome Measures ,030212 general & internal medicine ,Aged ,Neck pain ,business.industry ,Epidural steroid injection ,Minimal clinically important difference ,Odds ratio ,Middle Aged ,medicine.disease ,humanities ,Oswestry Disability Index ,Analgesics, Opioid ,Opioid ,Back Pain ,Radicular pain ,Anesthesia ,Female ,Steroids ,Surgery ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background Context Chronic opioid therapy is associated with worse patient-reported outcomes (PROs) following spine surgery. However, little literature exists on the relationship between opioid use and PROs following epidural steroid injections for radicular pain. Purpose We evaluated the association between pre-injection opioid use and PROs following spine epidural steroid injection. Study Design This study is a retrospective analysis of a prospective longitudinal registry database. Patient Sample A total of 392 patients within our database who were undergoing epidural steroid injections (ESIs) at our institution for degenerative structural spine diagnoses and met our inclusion criteria were included in this study. Outcome Measures Patient-reported outcomes for disability (Oswestry Disability Index/Neck Disability Index [ODI/NDI)]), quality of life (EuroQol-5D [EQ-5D]), and pain (Numerical Rating Scale scores for back pain, neck pain, leg pain, and arm pain [NRS-BP/NP/LP/AP]) were assessed at baseline and at 3 and 12 months post-injection. Methods Multivariable proportional odds logistic regression models were created to examine the relationship between pre-injection opioid use and post-injection PROs. A logistic regression with Bayesian Markov chain Monte Carlo parameter estimation was used to investigate a possible cutoff value of pre-injection opioid use above which the effectiveness of ESI (as measured by minimum clinically important difference [MCID] for ODI/NDI) decreases. Results A total of 276 patients with complete 12-month follow-up following ESI were analyzed. The mean pre-injection daily morphine equivalent amount (MEA) was 14.7 mg (95% confidence interval [CI] 12.4 mg–19.1 mg) for the cohort. Pre-injection opioid use was associated with slightly higher odds of worse disability (odds ratio [OR] 1.03, p=.03) and leg/arm pain (OR 1.01, p=.04) scores at 3 months post-injection only. No significant association between pre-injection opioid use and MCID for ODI/NDI was found, although a cutoff of 55.5 mg/day might serve as a significant threshold. Conclusion Increased pre-injection opioid use does not impact long-term outcomes after ESIs for degenerative spine diseases. A pre-injection MEA around 50 mg/day may represent a threshold above which the 3-month effectiveness of ESI for back- and neck-related disability decreases. Epidural steroid injection is an effective treatment modality for pain in patients using opioids, and can be part of a multimodal strategy for opioid independence.
- Published
- 2018
- Full Text
- View/download PDF
10. Pre-Injection Opioid Use as a Predictor of Adverse Postinjection Patient-Reported Outcomes following Epidural Steroid Injections for Degenerative Spine Disease
- Author
-
Ahilan Sivaganesan, Kristin R. Archer, Silky Chotai, Clinton J. Devin, and Johnny J. Wei
- Subjects
Spine (zoology) ,medicine.medical_specialty ,Epidural steroid ,business.industry ,Anesthesia ,Opioid use ,Medicine ,Surgery ,Orthopedics and Sports Medicine ,Neurology (clinical) ,Disease ,business - Published
- 2017
- Full Text
- View/download PDF
11. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
- Author
-
Thomas R. Caulfield, John A. Copland, Laura A. Marlow, Winston Tan, Christina A. von Roemeling, Johnny J. Wei, Kevin J. Wu, Han W. Tun, and Simon J. Cooper
- Subjects
Cancer Research ,Gene knockdown ,Sunitinib ,Pharmacology ,Biology ,medicine.disease ,Temsirolimus ,Article ,Kidney Neoplasms ,Pazopanib ,Clear cell renal cell carcinoma ,Oncology ,In vivo ,Sirolimus ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,lipids (amino acids, peptides, and proteins) ,Female ,Tyrosine kinase ,Carcinoma, Renal Cell ,Stearoyl-CoA Desaturase ,medicine.drug - Abstract
Purpose: We set out to identify Stearoyl-CoA desaturase 1 (SCD1) as a novel molecular target in clear cell renal cell carcinoma (ccRCC) and examine its role in tumor cell growth and viability in vitro and in vivo independently as well as in combination with current U.S. Food and Drug Administration (FDA)-approved regimens. Experimental Design: Patient normal and ccRCC tissue samples and cell lines were examined for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through use of a small molecule inhibitor, A939572, were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Therapeutic models of synergy were evaluated utilizing pharmacologic inhibition of SCD1 with the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus. Results: Our studies identify increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decreased tumor cell proliferation and induced apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of A939572-treated or SCD1 lentiviral knockdown samples, induction of endoplasmic reticulum stress response signaling was observed, providing mechanistic insight for SCD1 activity in ccRCC. Furthermore, combinatorial application of A939572 with temsirolimus synergistically inhibited tumor growth in vitro and in vivo. Conclusions: Increased SCD1 expression supports ccRCC viability and therefore we propose it as a novel molecular target for therapy either independently or in combination with an mTOR inhibitor for patients whose disease cannot be remedied with surgical intervention, such as in cases of advanced or metastatic disease. Clin Cancer Res; 19(9); 2368–80. ©2013 AACR.
- Published
- 2013
12. Right Versus Left Cuff Position for Upper Airway Stimulation.
- Author
-
Arambula AM, Bon-Nieves A, Alapati R, Wei J, Wagoner S, Lawrence A, Renslo B, Rouse D, and Larsen C
- Subjects
- Female, Humans, Middle Aged, Aged, Male, Retrospective Studies, Nose, Treatment Outcome, Hypoglossal Nerve, Electric Stimulation Therapy, Larynx, Sleep Apnea, Obstructive surgery
- Abstract
Objective: Upper airway stimulation (UAS) is a treatment option for obstructive sleep apnea in which electrical stimulation is applied to the hypoglossal nerve. Nerve branches that control tongue protrusion are located inferiorly. Due to positioning, left-sided implants are typically placed with an inferiorly oriented electrode cuff (L-down) as opposed to superiorly on the right (R-up). In this study, we assess the impact of left- versus right-sided UAS on patient outcomes., Study Design: Retrospective cohort study., Setting: Tertiary Academic Medical Center., Methods: Patients who underwent UAS implantation between 2016 and 2021 with an L-down or R-up oriented cuff as confirmed by X-ray were included. Data were collected retrospectively. Most recent sleep study variables were used for analysis., Results: A total of 190 patients met the inclusion criteria. The average age was 61.0 ± 11.0 years, with 55 (28.9%) females. L-down orientation was present in 21 (11.1%) patients vs 169 (88.9%) R-up. Indications for L-down included hunting/shooting (n = 15), prior radiation/surgery (n = 4), central port (n = 1), and brachial plexus injury (n = 1). Adherence was higher among L-down patients (47.1 vs 41.0 hours use/week, P = .037) in univariate analysis, with a similar time to adherence data collection (4.4 vs 4.2 months, P = .612), though this finding was not maintained in the multivariate regression analysis. Decrease in apnea-hypopnea index (21.3 vs 22.8, P = .734), treatment success (76.5% vs 84.0%, P = .665), functional threshold (1.5 vs 1.6, P = .550), therapeutic amplitude (2.3 vs 2.4, P = .882), and decrease in Epworth Sleepiness Scale (4.9 vs 2.6, P = .060) were not significantly different between cohorts., Conclusion: This study is the first to examine the orientation of the UAS electrode cuff concerning the electrodes' natural position and the potential effect on postoperative outcomes. Our study found no significantly different treatment outcomes between the L-down versus R-up cohort, with the exception of device adherence, which was significantly higher in the L-down group on univariate analysis though not on multivariate analysis. Future studies with larger patient cohorts are needed to further investigate this potential relationship between treatment outcomes and electrode cuff orientation., (© 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
13. The Association of the Pulmonary Artery Pulsatility Index and Right Ventricular Function after Cardiac Surgery.
- Author
-
Wei J, Kee A, Dukes R, Franke J, Leonardo V, and Flynn BC
- Abstract
Background: The pulmonary artery pulsatility index (PAPi) has been shown to correlate with right ventricular (RV) failure in patients with cardiac disease. However, the association of PAPi with right ventricular function following cardiac surgery is not yet established., Methods: PAPi and other hemodynamic variables were obtained postoperatively for 959 adult patients undergoing cardiac surgery. The association of post-bypass right ventricular function and other clinical factors to PAPi was evaluated using linear regression. A propensity-score matched cohort for PAPi ≥ 2.00 was used to assess the association of PAPi with postoperative outcomes., Results: 156 patients (16.3%) had post-bypass right ventricular dysfunction defined by visualization on transesophageal echocardiography. There was no difference in postoperative PAPi based on right ventricular function (2.12 vs. 2.00, p =0.21). In our matched cohort ( n = 636), PAPi < 2.00 was associated with increased incidence of acute kidney injury (23.0% vs 13.2%, p < 0.01) and ventilator time (6.0 hours vs 5.6 hours, p =0.04) but not with 30-day mortality or intensive care unit length of stay., Conclusion: In a general cohort of patients undergoing cardiac surgery, postoperative PAPi was not associated with postcardiopulmonary bypass right ventricular dysfunction. A postoperative PAPi < 2 may be associated with acute kidney injury., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2024 Johnny Wei et al.)
- Published
- 2024
- Full Text
- View/download PDF
14. Postoperative Pulmonary Artery Pulsatility Index Improves Prediction of Right Ventricular Failure After Left Ventricular Assist Device Implantation.
- Author
-
Wei J, Franke J, Kee A, Dukes R, Leonardo V, and Flynn BC
- Subjects
- Adult, Humans, Retrospective Studies, Pulmonary Artery diagnostic imaging, Risk Factors, Heart-Assist Devices adverse effects, Thoracic Surgical Procedures, Heart Failure surgery, Ventricular Dysfunction, Right diagnostic imaging, Ventricular Dysfunction, Right etiology
- Abstract
Objectives: This study evaluated whether the postoperative pulmonary artery pulsatility index (PAPi) is associated with postoperative right ventricular dysfunction after durable left ventricular assist device (LVAD) implantation., Design: Single-center retrospective observational cohort study., Setting: The University of Kansas Medical Center, a tertiary-care academic medical center., Participants: Sixty-seven adult patients who underwent durable LVAD implantation between 2017 and 2019., Interventions: All patients underwent open cardiac surgery with cardiopulmonary bypass under general anesthesia with pulmonary artery catheter insertion., Measurements and Main Results: Clinical and hemodynamic data were collected before and after surgery. The Michigan right ventricular failure risk score and the European Registry for Patients with Mechanical Circulatory Support score were calculated for each patient. The primary outcome was right ventricular failure, defined as a composite of right ventricular mechanical circulatory support, inhaled pulmonary vasodilator therapy for 48 hours or greater, or inotrope use for 14 days or greater or at discharge. Thirty percent of this cohort (n = 20) met the primary outcome. Preoperative transpulmonary gradient (odds ratio [OR] 1.15, 95% CI 1.02-1.28), cardiac index (OR 0.83, 95% CI 0.71-0.98), and postoperative PAPi (OR 0.85, 95% CI 0.75-0.97) were the only hemodynamic variables associated with the primary outcome. The addition of postoperative PAPi was associated with improvement in the predictive model performance of the Michigan score (area under the receiver operating characteristic curve 0.73 v 0.56, p = 0.03). An optimal cutoff point for postoperative PAPi of 1.56 was found., Conclusions: The inclusion of postoperative PAPi offers more robust predictive power for right ventricular failure in patients undergoing durable LVAD implantation, compared with the use of existing risk scores alone., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Comparing the associations of central venous pressure and pulmonary artery pulsatility index with postoperative renal injury.
- Author
-
Wei J, Houchin A, Nazir N, Leonardo V, and Flynn BC
- Abstract
Objective: Cardiac surgery-associated acute kidney injury (CS-AKI) is associated with significant morbidity and mortality. We investigated the association of postoperative central venous pressure (CVP) and pulmonary artery pulsatility index (PAPi) with the development of CS-AKI., Methods: This was a single-center, retrospective cohort study of patients undergoing cardiac surgery. CVP and PAPi were acquired hourly postoperatively and averaged for up to 48 h. PAPi was calculated as [(Pulmonary Artery Systolic Pressure-Pulmonary Artery Diastolic Pressure) / CVP]. The primary aim was CS-AKI. Secondary aims were need for renal replacement therapy (RRT), hospital and 30-day mortality, total ventilator and intensive care unit hours, and hospital length of stay. Logistic regression was used to calculate odds of development of renal injury and need for RRT., Results: One thousand two hundred eighty-eight patients were included. The average postoperative CVP was 10.3 mmHg and average postoperative PAPi was 2.01. Patients who developed CS-AKI ( n = 384) had lower PAPi (1.79 vs. 2.11, p < 0.01) and higher CVP (11.5 vs. 9.7 mmHg, p < 0.01) than those who did not. Lower PAPi and higher CVP were also associated with each secondary aim. A standardized unit decrease in PAPi was associated with increased odds of CS-AKI (OR 1.39, p < 0.01) while each unit increase in CVP was associated with both increased odds of CS-AKI (OR 1.56, p < 0.01) and postoperative RRT (OR 1.49, p = 0.02)., Conclusions: Both lower PAPi and higher CVP values postoperatively were associated with the development of CS-AKI but only higher CVP was associated with postoperative RRT use. When differences in values are standardized, CVP may be more associated with development of CS-AKI when compared to PAPi., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Wei, Houchin, Nazir, Leonardo and Flynn.)
- Published
- 2022
- Full Text
- View/download PDF
16. Molecular Cardioprotection and the Role of Exosomes: The Future Is Not Far Away.
- Author
-
Wei J, Hollabaugh C, Miller J, Geiger PC, and Flynn BC
- Subjects
- Humans, Male, Exosomes
- Abstract
Heart disease is the leading cause of death in men and women in the United States. During the past several decades, research into the role of specific intracellular mediators, called exosomes, has advanced the understanding of molecular cardioprotection. Exosomes and the micro-RNAs within them may be potential targets for the development of genetically engineered or biosimilar medications for patients in heart failure or with ischemic cardiac disease. This review discusses anesthetic implications of exosome production and the future micro-RNA applications for cardioprotection., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.
- Author
-
Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, and Copland JA
- Subjects
- Cell Line, Tumor, Cell Proliferation genetics, Down-Regulation, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Humans, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Cell Movement genetics, Genomics methods, Kidney Neoplasms genetics, Kidney Neoplasms pathology
- Abstract
Currently there is a lack of targeted therapies that lead to long-term attenuation or regression of disease in patients with advanced clear cell renal cell carcinoma (ccRCC). Our group has implemented a high-throughput genetic analysis coupled with a high-throughput proliferative screen in order to investigate the genetic contributions of a large cohort of overexpressed genes at the functional level in an effort to better understand factors involved in tumor initiation and progression. Patient gene array analysis identified transcripts that are consistently elevated in patient ccRCC as compared to matched normal renal tissues. This was followed by a high-throughput lentivirus screen, independently targeting 195 overexpressed transcripts identified in the gene array in four ccRCC cell lines. This revealed 31 'hits' that contribute to ccRCC cell proliferation. Many of the hits identified are not only presented in the context of ccRCC for the first time, but several have not been previously linked to cancer. We further characterize the function of a group of hits in tumor cell invasion. Taken together these findings reveal pathways that may be critical in ccRCC tumorigenicity, and identifies novel candidate factors that could serve as targets for therapeutic intervention or diagnostic/prognostic biomarkers for patients with advanced ccRCC.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.